Imuran (Azathioprine)

Azathioprine is a prodrug that is converted inside cells to 6‑mercaptopurine. This metabolite blocks the synthesis of purine nucleotides, which are essential building blocks for DNA and RNA. By limiting nucleotide production, the drug reduces the proliferation of rapidly dividing immune cells, thereby suppressing abnormal immune activity.

The dose of Imuran is individualized by the prescribing clinician. Factors such as the specific condition being treated, patient weight, renal and hepatic function, and laboratory monitoring results (e.g., blood counts) guide the selection of an appropriate dose. Patients should follow the prescriber’s instructions exactly.

Azathioprine is classified as pregnancy category D, indicating evidence of risk to the fetus. It may be used only when the potential benefit justifies the risk. Breastfeeding is generally not recommended while on azathioprine because the drug can be excreted in milk. Consultation with a healthcare professional is essential.

To order Imuran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Both Imuran (azathioprine) and mycophenolate mofetil are oral immunosuppressants used in transplant and autoimmune settings. Azathioprine acts by inhibiting purine synthesis via 6‑mercaptopurine, while mycophenolate blocks inosine monophosphate dehydrogenase, a different step in the pathway. Their safety profiles differ; azathioprine is more associated with bone‑marrow suppression, whereas mycophenolate carries a higher risk of gastrointestinal upset.

Imuran tablets should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Imuran is taken orally as a tablet. The tablet should be swallowed whole with a glass of water. It may be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals.

The most serious adverse effects of Imuran include severe bone‑marrow suppression leading to pancytopenia, significant liver injury (hepatotoxicity), increased susceptibility to serious infections, pancreatitis, and a rare but heightened risk of certain malignancies such as lymphomas or skin cancers. Regular laboratory monitoring helps detect these risks early.

Imuran is contraindicated in individuals with known hypersensitivity to azathioprine or any of its components, those with severe bone‑marrow suppression, active uncontrolled infections, and patients who are pregnant unless the therapeutic benefit outweighs the potential fetal risk. It should also be avoided in patients with severe hepatic impairment.